Kymera Therapeutics KYMR 深 滬
等待開盤 11-26 09:30:00 美东时间
66.04
+0.450
+0.69%
華盛通- 最 高67.195
- 今 開65.80
- 成交量 67.58万股
- 最 低 63.86
- 昨 收 65.59
- 總市值 47.22亿
- 52周最高 68.80
- 市盈率 靜 --
- 換手率 0.95%
- 52周最低 19.445
- 委 比 -64.52%
- 總股本 7149.76万
- 歷史最高 91.92
- 量 比 1.01
- 振 幅 5.08%
- 歷史最低 9.60
- 每 手 1
- 風險率 10.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kymera Therapeutics to Participate in Upcoming December Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in fireside chats at three upcoming investor events in December 2025. The events include the Piper Sandler 37thAnnual Healthcare Conference in New York on December 2, the Citi 2025 Global Healthcare Conference in Miami on December 3, and the Evercore 8thAnnual Healthcare Conference in Coral Gables on December 4. Live webcasts of the presentations will be ...
11-24 12:00
B. Riley Securities Remains a Buy on Kymera Therapeutics (KYMR)
In a report released yesterday, Mayank Mamtani from B. Riley Securities maintai...
11-06 13:55
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
10 Analysts Have This To Say About Kymera Therapeutics
Across the recent three months, 10 analysts have shared their insights on Kymer...
11-05 19:45
Kymera Therapeutics Q3 EPS $(0.94) Misses $(0.83) Estimate, Sales $2.764M Miss $18.852M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.83) by 13.12 percent. This is a 14.63 percent decrease over losses of $(0.82) per share
11-04 20:02
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90
Guggenheim analyst Brad Canino assumes Kymera Therapeutics (NASDAQ:KYMR) with a Buy rating and announces Price Target of $90.
11-03 21:14
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Kymera Therapeutics announced its participation in multiple investor events in November 2025, including fireside chats at conferences in Boston, Palm Beach, New York, and London. The events aim to discuss the company’s targeted protein degradation (TPD) technology for immunological diseases. Live webcasts and replays of the presentations will be available on Kymera’s website.
11-03 12:00
Kymera Therapeutics Presents New Preclinical Data For KT-579, Oral IRF5 Degrader, Demonstrating Disease-Modifying Activity Across Multiple Immuno-Inflammatory Diseases, At ACR 2025
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically
10-27 19:12
